Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna Pharmaceuticals to Present at the Second Annual BIO National Venture Conference View HTML
Toggle Summary Dicerna Pharmaceuticals Secures Exclusive Worldwide Right to Sublicense the Dicer Substrate Technology RNAi Platform View HTML
Toggle Summary Dicerna Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference View HTML
Toggle Summary Dicerna Pharmaceuticals Announces New Data That Show Dicer-substrate RNA Molecules Produce More Potent, Longer Lasting Gene Silencing Than Shorter siRNA Molecules; Results Published in Journal of Biomolecular Techniques View HTML
Toggle Summary Dicerna Co-Founder and Scientific Advisory Board Chair Present at American Association of Pharmaceutical Scientists 2008 Meeting Exposition View HTML
Toggle Summary Dicerna Pharmaceuticals, an RNA Interference Company, to Present at Discovery on Target Conference View HTML
Toggle Summary Dicerna Pharmaceuticals to Present at First Annual Boston Biotech R&D Conference View HTML
Toggle Summary Dicerna Pharmaceuticals Appoints Leading Experts to Scientific Advisory Board View HTML
Toggle Summary Dicerna Pharmaceuticals Announces Preclinical Findings Highlighting Novel Approach to Maximizing Dicer-Substrate Small Interfering RNAs (DsiRNAs) in Rheumatoid Arthritis; Data Appear Published by Molecular Therapy View HTML
Toggle Summary Dicerna Pharmaceuticals, a Second Generation RNA Interference Company, Completes Second Closing of Series A Financing; Unveils Strategic Focus View HTML